DK0489837T4 - Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand - Google Patents

Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand

Info

Publication number
DK0489837T4
DK0489837T4 DK90913598.0T DK90913598T DK0489837T4 DK 0489837 T4 DK0489837 T4 DK 0489837T4 DK 90913598 T DK90913598 T DK 90913598T DK 0489837 T4 DK0489837 T4 DK 0489837T4
Authority
DK
Denmark
Prior art keywords
receptor
present
beta
alpha
ligand
Prior art date
Application number
DK90913598.0T
Other languages
English (en)
Other versions
DK0489837T3 (da
Inventor
Elizabeth Wayner
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0489837(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of DK0489837T3 publication Critical patent/DK0489837T3/da
Application granted granted Critical
Publication of DK0489837T4 publication Critical patent/DK0489837T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
DK90913598.0T 1989-09-01 1990-08-31 Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand DK0489837T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40238989A 1989-09-01 1989-09-01
PCT/US1990/004978 WO1991003252A1 (en) 1989-09-01 1990-08-31 Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction

Publications (2)

Publication Number Publication Date
DK0489837T3 DK0489837T3 (da) 2004-03-01
DK0489837T4 true DK0489837T4 (da) 2013-11-18

Family

ID=23591680

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90913598.0T DK0489837T4 (da) 1989-09-01 1990-08-31 Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand

Country Status (19)

Country Link
EP (2) EP0489837B2 (da)
JP (1) JP3357359B2 (da)
KR (1) KR100188459B1 (da)
AT (1) ATE253642T1 (da)
AU (1) AU654657B2 (da)
CA (1) CA2065292C (da)
DD (1) DD297562A5 (da)
DE (3) DE69034116T3 (da)
DK (1) DK0489837T4 (da)
ES (1) ES2210225T5 (da)
FI (2) FI116793B (da)
GR (2) GR1001161B (da)
IE (2) IE20040028A1 (da)
IL (3) IL95501A (da)
LU (1) LU91273I2 (da)
NL (1) NL300240I2 (da)
NZ (1) NZ235131A (da)
PT (1) PT95180A (da)
WO (1) WO1991003252A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
AU3420693A (en) * 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
JPH07506091A (ja) 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
EP0670735B1 (en) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
EP0682529B2 (en) † 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
JP4031028B2 (ja) † 1993-03-18 2008-01-09 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 特異的プライマー及びプローブセットを使用するｈｌａ−ｂタイピングの方法
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2182013C (en) * 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
FR2724393A1 (fr) * 1994-09-12 1996-03-15 Inst Nat Sante Rech Med Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (en) * 1996-03-22 1997-10-02 Kao Corporation External skin-care composition
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
US7125650B2 (en) 2004-07-20 2006-10-24 Roberts David H Method for bump exposing relief image printing plates
KR20230021758A (ko) 2011-05-02 2023-02-14 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells

Also Published As

Publication number Publication date
EP0489837B1 (en) 2003-11-05
WO1991003252A1 (en) 1991-03-21
JP3357359B2 (ja) 2002-12-16
EP0489837A1 (en) 1992-06-17
IL113261A0 (en) 1995-07-31
DE69034116T2 (de) 2004-08-26
IE903169A1 (en) 1991-03-13
DE122006000044I1 (de) 2007-04-19
DE69034116D1 (de) 2003-12-11
JPH05503070A (ja) 1993-05-27
DE122006000044I2 (de) 2011-01-13
GR1001161B (el) 1993-05-24
IE20040028A1 (en) 2004-05-05
FI116793B (fi) 2006-02-28
EP1366769A1 (en) 2003-12-03
AU654657B2 (en) 1994-11-17
ES2210225T5 (es) 2014-02-04
AU6354290A (en) 1991-04-08
LU91273I2 (fr) 2006-10-10
FI920899A0 (fi) 1992-02-28
FI20050941A (fi) 2005-09-21
DK0489837T3 (da) 2004-03-01
PT95180A (pt) 1991-05-22
IL113261A (en) 1996-10-16
GR1001372B (el) 1993-10-29
ES2210225T3 (es) 2004-07-01
CA2065292A1 (en) 1991-03-02
NL300240I2 (nl) 2007-03-01
EP0489837A4 (en) 1993-06-16
FI118842B (fi) 2008-04-15
IL95501A (en) 1997-04-15
DE69034116T3 (de) 2014-06-18
DD297562A5 (de) 1992-01-16
CA2065292C (en) 2001-05-29
KR920703086A (ko) 1992-12-17
NL300240I1 (nl) 2006-10-02
NZ235131A (en) 1993-03-26
KR100188459B1 (ko) 1999-06-01
GR900100648A (en) 1992-01-20
ATE253642T1 (de) 2003-11-15
EP0489837B2 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
DK0489837T4 (da) Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand
Walsh et al. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner.
EP0371036A4 (en) METHOD FOR REDUCING DAMAGE CAUSED TO TISSUE AT AN INFLAMMATION SITE USING A MONOCLONAL ANTIBODY.
DE69326759T2 (de) Lymphozytenaktivierungsantigen hb15 ein mitglied der immunglobulin superfamilie
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
DE69125025D1 (de) Verfahren zur homo- oder copolymerisation von ethen
DE3788292T2 (de) Verwendung von Tetrathiafulvalenen in bioelectrochemischen Verfahren.
IT1147852B (it) Impianto di avviso di prossimita' del suolo per aerei,con commutazione di modo in base al tempo
DE3766514D1 (de) 1,2,3,4-tetrahydro-6-substituierte-4-aryl(oder heterocyclo)-3-substituierte-2-thioxo(oder oxo)-5-pyrimidincarboxylsaeuren und -ester.
FI883351A (fi) Diagnostisk metod foer paovisande av stoerningar i rna-as l.
LU81242A1 (fr) Composition en vue de reduire le taux de phenylalanine dans le sang,et son procede d'utilisation
DE378732T1 (de) Serum-proteine in bezug auf autoimmunerkrankungen.
IT8521468A0 (it) Procedimento per ottenere interferon leucocitario alfa-2dell'uomo.
DE68925032T2 (de) Leukozyten-adhäsions-inhibitor.
IT8248817A0 (it) Composizione per eliminare impurezze da catalizzatori e metodo per lasua applicazione e rigenerazioni didetti catalizzatori
KR870005645A (ko) 신규세포 생장조절 인자
Hyman et al. Protease inhibitors reduce the reverse passive Arthus reaction
Sorg Modulation of macrophage functions by lymphokines
Kakishita et al. Thrombin-induced vascular responses in rabbit aorta-modulation of endothelium
Maruyama et al. Upregulation of thrombomodulin on human cultured umbilical vein endothelial cells by cAMP
KR900701834A (ko) 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법
DE29518160U1 (de) Vorrichtung zum Anbringen von Verstärkungsstreifen an dem Rücken von Buchblöcken